Evaluation of Diagnostic Efficacy of Anticyclic Citrullinated Peptide Antibody in Diagnosis of Rheumatoid Arthritis
Background: The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA...
Saved in:
| Published in | International journal of applied and basic medical research Vol. 15; no. 3; pp. 178 - 183 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
India
Wolters Kluwer - Medknow
01.07.2025
Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd |
| Edition | 2 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2229-516X 2248-9606 |
| DOI | 10.4103/ijabmr.ijabmr_128_25 |
Cover
| Abstract | Background:
The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA.
Aim:
The present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP.
Materials and Methods:
The study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria.
Results:
The specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%.
Conclusions:
The diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment. |
|---|---|
| AbstractList | Background:The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA.Aim:The present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP.Materials and Methods:The study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria.Results:The specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%.Conclusions:The diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment. Background: The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA. Aim: The present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP. Materials and Methods: The study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria. Results: The specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%. Conclusions: The diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment. Background: The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA. Aim: The present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP. Materials and Methods: The study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria. Results: The specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%. Conclusions: The diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment. Keywords: Anticyclic citrullinated peptide, diagnostic efficacy, erythrocyte sedimentation rate, rheumatoid arthritis, serum C-reactive protein The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA.BackgroundThe prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA.The present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP.AimThe present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP.The study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria.Materials and MethodsThe study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria.The specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%.ResultsThe specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%.The diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment.ConclusionsThe diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment. The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA. The present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP. The study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria. The specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%. The diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment. The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), are nonindicative in the initial stages of disease as well as nonspecific. The latest marker introduced for detection of RA is anticyclic citrullinated peptide (anti-CCP), which can help in early diagnosis and check the progression of severity of RA. The present study was designed to evaluate the role of anti-CCP antibody in the diagnosis of RA in early stage of disease as compared to ESR and CRP. The study population consisted of 325 participants presenting to the orthopedic department, AIMSR, with suspected clinical features of arthritis. All enrolled participants were subjected to demographic and biochemical analysis after taking a detailed history and following the inclusion and exclusion criteria. The specificity and sensitivity of anti-CCP antibody for the diagnosis of RA, as compared to ESR and CRP, were observed to be 75.77% and 97.7%, respectively. Further, the negative and positive predictive value was found to be as high as 98% and 75.77%, while the likelihood ratios of a positive and negative test were found to be 3.88 and 0.06, respectively. The diagnostic odds ratio was observed to be 133.44, while the accuracy of anti-CCP antibody in the diagnosis of RA was observed to be 84%. The diagnostic potential of anti-CCP antibody can be useful for specific and sensitive diagnosis of RA disease in early stage, helping the clinicians in early and timely administration of treatment. |
| Audience | Academic |
| Author | Singh, Japjot Gupta, Kapil Bansal, Nitin |
| Author_xml | – sequence: 1 givenname: Japjot surname: Singh fullname: Singh, Japjot – sequence: 2 givenname: Kapil surname: Gupta fullname: Gupta, Kapil – sequence: 3 givenname: Nitin surname: Bansal fullname: Bansal, Nitin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40937027$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl2LEzEUhgdZcT_cfyAyIIg3U_Mxk8xclm53FRYUUfAuZPKxTTeT1CRj6b83Y1u1IiYXJ7w878mB814WZ847VRQvIJjVEOC3Zs37Icz2hUHUMtQ8KS4QqtuqI4CcTW_UVQ0kX8-L6xjXIB-CKCH1s-K8Bh2mANGLIi6_czvyZLwrvS5vDH9wPiYjyqXWRnCxm-S5y8pO2CwvTAqjtcbxpGT5UW2Skeon0Hu5K4079jBxcn5aqXHgyRtZzkNaBZNMfF481dxGdX2oV8WX2-Xnxbvq_sPd-8X8vhI1gqaCPUBcUIh6iVrAkQKtVEBTyTGhEGIN2lYCiAFsOq573fREyUZhypueUg7xVfFm33cT_LdRxcQGE4Wyljvlx8gwqru27jqMM_rqL3Ttx-DydBMFMcINqX9TD9wqZpz2KXAxNWXztkENorQlmZr9g8pXqsGIvEdtsn5ieP2HYaW4Tavo7TgtJZ6CLw9Tjv2gJNsEM_CwY8d1ZqDeAyL4GIPSvxAI2BQcdkjMSXCy7XZv23qbVIiPdtyqwPIXj85v_-tlkLbsmCH8Az5j0NQ |
| Cites_doi | 10.3390/medicina57050503 10.1007/s00296-002-0251-6 10.1309/LMZYTSO5RHIHV93T 10.1007/s00296-009-0854-2 10.1182/blood-2018-99-117260 10.1111/jocd.12508 10.4103/picr.PICR_41_18 10.1111/1756-185X.12621 10.1186/s12889-023-17156-8 10.1001/jama.2023.24647 10.25122/jml-2023-0158 10.1016/S0895-4356(03)00177-X 10.3390/cells9040880 10.1016/j.jaut.2020.102405 10.1002/art.20773 10.2217/17455057.4.2.195 10.1002/art.20044 10.1097/BOR.0b013e32805e87bf 10.1016/S0140-6736(16)30173-8 10.3390/bios13030381 10.3389/fmed.2022.909879 10.1177/014107680409700903 10.1111/j.1553-2712.1996.tb03538.x 10.1136/ard.2006.051391 10.1084/jem.20160792 10.1016/j.jaut.2009.12.007 10.1155/2012/285854 |
| ContentType | Journal Article |
| Copyright | 2025 International Journal of Applied and Basic Medical Research Copyright: © 2025 International Journal of Applied and Basic Medical Research. COPYRIGHT 2025 Medknow Publications and Media Pvt. Ltd. 2025. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2025 International Journal of Applied and Basic Medical Research – notice: Copyright: © 2025 International Journal of Applied and Basic Medical Research. – notice: COPYRIGHT 2025 Medknow Publications and Media Pvt. Ltd. – notice: 2025. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION NPM K9. 7X8 |
| DOI | 10.4103/ijabmr.ijabmr_128_25 |
| DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2248-9606 |
| Edition | 2 |
| EndPage | 183 |
| ExternalDocumentID | A852527786 40937027 10_4103_ijabmr_ijabmr_128_25 IJABMR-15-178 |
| Genre | Journal Article |
| GeographicLocations | India |
| GeographicLocations_xml | – name: India |
| GroupedDBID | 04Q 04T 53G 7X7 8FI 8FJ AAKDD ABDBF ABUWG ACGFS ACUHS ADBBV ADJBI ADRAZ AFKRA ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BENPR BPHCQ CCPQU DIK EOJEC ESX FYUFA GX1 H13 HMCUK HYE IHR IHW ITC KQ8 M48 OBODZ OK1 OVD PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RMW RPM TEORI TUS UKHRP W3E AAYXX CITATION NPM K9. 7X8 |
| ID | FETCH-LOGICAL-c421i-1b02ac712bd280a2e08de0f7da367113f088d0130159afbf5b6ed5e37a5b77a13 |
| IEDL.DBID | M48 |
| ISSN | 2229-516X |
| IngestDate | Fri Sep 12 17:04:16 EDT 2025 Thu Aug 21 08:40:51 EDT 2025 Wed Aug 27 16:51:07 EDT 2025 Tue Aug 26 03:42:06 EDT 2025 Tue Aug 26 02:12:08 EDT 2025 Wed Sep 17 01:59:39 EDT 2025 Wed Aug 27 16:41:34 EDT 2025 Thu Aug 28 06:15:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | erythrocyte sedimentation rate Anticyclic citrullinated peptide rheumatoid arthritis serum C-reactive protein diagnostic efficacy |
| Language | English |
| License | Copyright: © 2025 International Journal of Applied and Basic Medical Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c421i-1b02ac712bd280a2e08de0f7da367113f088d0130159afbf5b6ed5e37a5b77a13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4103/ijabmr.ijabmr_128_25 |
| PMID | 40937027 |
| PQID | 3241323564 |
| PQPubID | 2035635 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_3249849933 proquest_journals_3241323564 gale_infotracmisc_A852527786 gale_infotracacademiconefile_A852527786 gale_healthsolutions_A852527786 pubmed_primary_40937027 crossref_primary_10_4103_ijabmr_ijabmr_128_25 wolterskluwer_medknow_10_4103_ijabmr_ijabmr_128_25_178_Evaluati |
| PublicationCentury | 2000 |
| PublicationDate | 2025-07-01 |
| PublicationDateYYYYMMDD | 2025-07-01 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | India |
| PublicationPlace_xml | – name: India – name: Punjab |
| PublicationTitle | International journal of applied and basic medical research |
| PublicationTitleAlternate | Int J Appl Basic Med Res |
| PublicationYear | 2025 |
| Publisher | Wolters Kluwer - Medknow Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd |
| Publisher_xml | – name: Wolters Kluwer - Medknow – name: Medknow Publications and Media Pvt. Ltd – name: Medknow Publications & Media Pvt. Ltd |
| References | Sánchez-Tirado (R10-20250821) 2023; 13 Madan (R12-20250821) 2019; 13 Saha (R9-20250821) 2018; 132 Monaghan (R30-20250821) 2021; 57 Avouac (R34-20250821) 2006; 65 Ferucci (R36-20250821) 2005; 52 Khudhair (R31-20250821) 2023; 16 Raine (R22-20250821) 2022; 9 Aletaha (R5-20250821) 2020; 110 Saha (R24-20250821) 2023; 23 Mitchell (R1-20250821) 2007; 19 Buderer (R14-20250821) 1996; 3 Ranganathan (R32-20250821) 2018; 9 van Gaalen (R35-20250821) 2004; 50 Suresh (R18-20250821) 2004; 97 Behrens (R21-20250821) 2010; 35 Smolen (R4-20250821) 2016; 388 Šimundić (R27-20250821) 2009; 19 Shen (R11-20250821) 2015; 46 Gerosa (R20-20250821) 2008; 4 Papadopoulos (R26-20250821) 2003; 23 Glas (R33-20250821) 2003; 56 Feltner (R16-20250821) 2024; 331 Lephart (R23-20250821) 2018; 17 Wagner (R28-20250821) 2009; 29 Al-Shukaili (R29-20250821) 2012; 2012 Finckh (R2-20250821) 2022; 18 Handa (R13-20250821) 2016; 19 Landry (R8-20250821) 2017; 63 Tan (R7-20250821) 2016; 213 Lin (R3-20250821) 2020; 9 |
| References_xml | – volume: 57 start-page: 503 year: 2021 ident: R30-20250821 article-title: Foundational statistical principles in medical research: Sensitivity, specificity, positive predictive value, and negative predictive value publication-title: Medicina (Kaunas) doi: 10.3390/medicina57050503 – volume: 19 start-page: 203 year: 2009 ident: R27-20250821 article-title: Measures of diagnostic accuracy: Basic definitions publication-title: EJIFCC – volume: 23 start-page: 70 year: 2003 ident: R26-20250821 article-title: Early rheumatoid arthritis patients: Relationship of age publication-title: Rheumatol Int doi: 10.1007/s00296-002-0251-6 – volume: 13 start-page: 8 year: 2019 ident: R12-20250821 article-title: A study of correlation of disease severity with antibody titers in rheumatoid arthritis publication-title: J Clin Diagn Res – volume: 46 start-page: 226 year: 2015 ident: R11-20250821 article-title: Rheumatoid factor, anti-cyclic citrullinated peptide antibody, C-reactive protein, and erythrocyte sedimentation rate for the clinical diagnosis of rheumatoid arthritis publication-title: Lab Med doi: 10.1309/LMZYTSO5RHIHV93T – volume: 29 start-page: 1315 year: 2009 ident: R28-20250821 article-title: Antibody against mutated citrullinated vimentin: A new sensitive marker in the diagnosis of rheumatoid arthritis publication-title: Rheumatol Int doi: 10.1007/s00296-009-0854-2 – volume: 132 start-page: 4874 year: 2018 ident: R9-20250821 article-title: Erythrocyte deformability as a potential biomarker for chronic fatigue syndrome publication-title: Blood doi: 10.1182/blood-2018-99-117260 – volume: 17 start-page: 282 year: 2018 ident: R23-20250821 article-title: A review of the role of estrogen in dermal aging and facial attractiveness in women publication-title: J Cosmet Dermatol doi: 10.1111/jocd.12508 – volume: 9 start-page: 99 year: 2018 ident: R32-20250821 article-title: Understanding the properties of diagnostic tests – Part 2: Likelihood ratios publication-title: Perspect Clin Res doi: 10.4103/picr.PICR_41_18 – volume: 19 start-page: 440 year: 2016 ident: R13-20250821 article-title: Literature review of rheumatoid arthritis in India publication-title: Int J Rheum Dis doi: 10.1111/1756-185X.12621 – volume: 23 start-page: 2313 year: 2023 ident: R24-20250821 article-title: Gender-specific determinants of overweight and obesity among older adults in India: Evidence from a cross-sectional survey, 2017-18 publication-title: BMC Public Health doi: 10.1186/s12889-023-17156-8 – volume: 331 start-page: 335 year: 2024 ident: R16-20250821 article-title: Screening for speech and language delay and disorders in children 5 years or younger: Evidence report and systematic review for the US preventive services task force publication-title: JAMA doi: 10.1001/jama.2023.24647 – volume: 16 start-page: 1194 year: 2023 ident: R31-20250821 article-title: A study of the roles of some immunological biomarkers in the diagnosis of rheumatoid arthritis publication-title: J Med Life doi: 10.25122/jml-2023-0158 – volume: 56 start-page: 1129 year: 2003 ident: R33-20250821 article-title: The diagnostic odds ratio: A single indicator of test performance publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(03)00177-X – volume: 9 start-page: 880 year: 2020 ident: R3-20250821 article-title: Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis publication-title: Cells doi: 10.3390/cells9040880 – volume: 110 start-page: 102405 year: 2020 ident: R5-20250821 article-title: Precision medicine and management of rheumatoid arthritis publication-title: J Autoimmun doi: 10.1016/j.jaut.2020.102405 – volume: 52 start-page: 239 year: 2005 ident: R36-20250821 article-title: Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.20773 – volume: 4 start-page: 195 year: 2008 ident: R20-20250821 article-title: Rheumatoid arthritis: A female challenge publication-title: Womens Health (Lond) doi: 10.2217/17455057.4.2.195 – volume: 50 start-page: 709 year: 2004 ident: R35-20250821 article-title: Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study publication-title: Arthritis Rheum doi: 10.1002/art.20044 – volume: 19 start-page: 278 year: 2007 ident: R1-20250821 article-title: Early rheumatoid arthritis publication-title: Curr Opin Rheumatol doi: 10.1097/BOR.0b013e32805e87bf – volume: 388 start-page: 2023 year: 2016 ident: R4-20250821 article-title: Rheumatoid arthritis publication-title: Lancet doi: 10.1016/S0140-6736(16)30173-8 – volume: 13 start-page: 381 year: 2023 ident: R10-20250821 article-title: Serum autoantibody biomarkers for management of rheumatoid arthritis disease publication-title: Biosensors (Basel) doi: 10.3390/bios13030381 – volume: 18 start-page: 591 year: 2022 ident: R2-20250821 article-title: Global epidemiology of rheumatoid arthritis publication-title: Nat Rev Rheumatol – volume: 9 start-page: 909879 year: 2022 ident: R22-20250821 article-title: What is the impact of sex hormones on the pathogenesis of rheumatoid arthritis? publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2022.909879 – volume: 97 start-page: 421 year: 2004 ident: R18-20250821 article-title: Diagnosis of early rheumatoid arthritis: What the non-specialist needs to know publication-title: J R Soc Med doi: 10.1177/014107680409700903 – volume: 3 start-page: 895 year: 1996 ident: R14-20250821 article-title: Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity publication-title: Acad Emerg Med doi: 10.1111/j.1553-2712.1996.tb03538.x – volume: 65 start-page: 845 year: 2006 ident: R34-20250821 article-title: Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.051391 – volume: 63 start-page: e316 year: 2017 ident: R8-20250821 article-title: Causes and outcomes of markedly elevated C-reactive protein levels publication-title: Can Fam Physician – volume: 213 start-page: 1937 year: 2016 ident: R7-20250821 article-title: Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor publication-title: J Exp Med doi: 10.1084/jem.20160792 – volume: 35 start-page: 1 year: 2010 ident: R21-20250821 article-title: Mechanism by which HLA-DR4 regulates sex-bias of arthritis in humanized mice publication-title: J Autoimmun doi: 10.1016/j.jaut.2009.12.007 – volume: 2012 start-page: 285854 year: 2012 ident: R29-20250821 article-title: Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Omani patients with rheumatoid arthritis publication-title: Int J Rheumatol doi: 10.1155/2012/285854 |
| SSID | ssj0000627664 |
| Score | 2.300079 |
| Snippet | Background:
The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte... The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte sedimentation rate... Background: The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte... Background:The prevalent diagnostic tests available for rheumatoid arthritis (RA), i.e. rheumatoid factor, C-reactive protein (CRP), and erythrocyte... |
| SourceID | proquest gale pubmed crossref wolterskluwer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 178 |
| SubjectTerms | Antibodies Arthritis Blood C-reactive protein Comparative analysis Medical examination Original Article Peptides Rheumatoid arthritis Rheumatoid factor |
| SummonAdditionalLinks | – databaseName: Medknow Open Access Journals dbid: W3E link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEB_OE0QQ8fuqp1YQfLHaJE2TPsly7nEIJyIe7ltImoSr3rVye4fsf-9M2123gr74VEgmIcnMJJPOzC8AL73VhWU-ZFzHIisiqzPtlcrKyjEfWeF4oGzk44_l0UnxYSEXO_B6nQuz5b8vWC7eNt-sO794M3wMbqaGy2twnStWkQx_Fb__qBDgbtnjRdEb1Zlk5WLIlftrR5Oz6M8deetIuvWzI9f18nsfub51_hzegduj4ZjOBk7fhZ3Q3oMbx6Nr_D4s5xvc7rSL6fshhA6J0zmhRNh6RcWzFktW9RkWH1C-BSFyo7Xp008U3eJDT-A6v0qbdt1Hs6SWn0_DFVq3XeNpDKc9FtIDODmcfzk4ysYXFbK64KzJmMu5rRXjznOdWx5y7UMelbeiVIyJiHuOJ18mGjk2uihdGbwMQlnplLJMPITdtmvDHqSicELIEH2FTObauxwZrX2NJomrYskTyNZra34MwBkGLxzECzMyYcKLBJ4TA8yQ_rnROzPTkktOKHcJvOopSPMuLywu3JBAgOMhDKsJ5f6EEjWmnlavmWxGjV0aQQ5GLmRZJPBiU00tKQqtDd1VT1NpvCIKkcCjQTg2c8N7slB4x0_g3URazPmQ1vjPyRumtFmLyeP_7uEJ3OT0THEfVbwPuyhO4SnaTpfuWa8yvwBeGBrA priority: 102 providerName: Wolters Kluwer Health |
| Title | Evaluation of Diagnostic Efficacy of Anticyclic Citrullinated Peptide Antibody in Diagnosis of Rheumatoid Arthritis |
| URI | https://doi.org/10.4103/ijabmr.ijabmr_128_25 https://www.ncbi.nlm.nih.gov/pubmed/40937027 https://www.proquest.com/docview/3241323564 https://www.proquest.com/docview/3249849933 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA-1QikU8dvVqisIPu25STab3FM56pUiVEQ8vLeQbBK62u7Wuxa9_96Zze5xJ9aXXUgmIcn8ksyQ-SDkrTOqMNT5jKlQZEWgVaaclFk5ttQFWljm0Rv57FN5Ois-zsV8hww5W_sFXP5TtcN8UrPFxej3z9URbHiQX0cFzfn7-ruxl4tR_Gk4cDUTd8jd7sUIjfl6gT-ezUyWXUwpzGOdCVrOoz_drR3tkz1QgbjMMe_MxtX19wG-cYMd_GrxpXv5ozN037iuTu6Te72cmU4iMB6QHd88JHtn_Uv6I7KcrsN8p21IP0SLOyBOpxhUwlQrLJ40ULKqLqD4GN0zMIA3CKcu_YzGMM53BLZ1q7Ruhj7qJbb8cu5vQBhua4djOO9CJz0ms5Pp1-PTrE_AkFUFo3VGbc5MJSmzjqncMJ8r5_MgneGlpJQHOKIcPn2CTGSCDcKW3gnPpRFWSkP5E7LbtI1_RlJeWM6FD24MmGDK2RxwoVwFEowdh5IlJBvWVl_FOBsa9BNki-75scWWhLxGBujoLbrepnqiBBMMg-Il5F1HgdC5XhhYuOhvAOPBkFdblIdblLDBqu3qgcl6wKfmiC7GRVkk5M26Glui0Vrj25uOZqxAo-Q8IU8jONZzGzCVkKMttOjL6AX538lrKpUeYPL81r5fkH2G2Yo74-JDsgsw8S9BhLq2r7pdAd9vfPoHPeIciA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+Diagnostic+Efficacy+of+Anticyclic+Citrullinated+Peptide+Antibody+in+Diagnosis+of+Rheumatoid+Arthritis&rft.jtitle=International+journal+of+applied+and+basic+medical+research&rft.au=Singh%2C+Japjot&rft.au=Gupta%2C+Kapil&rft.au=Bansal%2C+Nitin&rft.date=2025-07-01&rft.issn=2229-516X&rft.volume=15&rft.issue=3&rft.spage=178&rft_id=info:doi/10.4103%2Fijabmr.ijabmr_128_25&rft_id=info%3Apmid%2F40937027&rft.externalDocID=40937027 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2229-516X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2229-516X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2229-516X&client=summon |